Phase II study of sunitinib malate in patients with recurrent high-grade glioma. (Q33392046)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Phase II study of sunitinib malate in patients with recurrent high-grade glioma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Johnny Duerinck

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Jacques De Greve

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

B Neyns

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

J Sadones

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

M Dujardin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

H Everaert

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

S Lv

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

O Tynninen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

N Nupponen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

A Michotte

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

25 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

491-501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20872043%20AND%20SRC:MED&resulttype=core&format=json

Malignant gliomas in adults

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Genetic alterations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0402-7

Expression of VEGF and its receptors in different brain tumors

21 January 2018

1 reference

12 December 2020

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

1 reference

12 December 2020

Invasion as limitation to anti-angiogenic glioma therapy

1 reference

12 December 2020

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

1 reference

12 December 2020

1 reference

12 December 2020

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

12 December 2020

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

1 reference

12 December 2020

EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

1 reference

12 December 2020

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020